Piramal Critical Care, a global leader in anesthesia, pain management, and intrathecal therapy, today announced the launch of MITIGO™ (Morphine Sulfate Injection, USP - Preservative-free) in 10 mg/mL and 25 mg/mL concentrations in the US market.
Piramal Critical Care will continue to work with wholesalers, hospitals, interventional pain doctors, and pain management centers across the country to ensure availability of MITIGO™ for patients with intractable chronic pain.
Peter DeYoung, Chief Executive Officer, Piramal Critical Care said: "Piramal Critical Care has established itself as the leader in U.S. intrathecal therapy with Gablofen® which we have successfully integrated post its acquisition from Mallinckrodt. We are pleased to support intrathecal therapy for pain management with FDA approval and our launch of MITIGO™. We continue to expand our leadership in intrathecal therapy through this launch, as well as in inhaled anesthesia and the injectable anesthesia and pain management drugs that we acquired from Janssen. We stay committed to executing on our strategy to expand our portfolio, address patient and customer needs, and deliver high quality critical care solutions to the market."
Shares of PIRAMAL ENTERPRISES LTD. was last trading in BSE at Rs.2661.15 as compared to the previous close of Rs. 2585.95. The total number of shares traded during the day was 43262 in over 2078 trades.
The stock hit an intraday high of Rs. 2675.05 and intraday low of 2586. The net turnover during the day was Rs. 114817611.